Symbols / KYMR Stock $83.55 -0.65% Kymera Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
KYMR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Nello Mainolfi M.D., Ph.D.
Exch · Country NGM · United States
Market Cap 6.87B
Enterprise Value 6.30B
Income -315.00M
Sales 51.48M
FCF (ttm) -139.26M
Book/sh 19.42
Cash/sh 7.91
Employees 253
Insider 10d —
IPO Aug 21, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -19.12
PEG —
P/S 133.51
P/B 4.30
P/C —
EV/EBITDA -18.08
EV/Sales 122.43
Quick Ratio 10.39
Current Ratio 10.81
Debt/Eq 5.23
LT Debt/Eq —
EPS (ttm) -3.58
EPS next Y -4.37
EPS Growth —
Revenue Growth 55.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-04-30
ROA -17.16%
ROE -27.09%
ROIC —
Gross Margin 0.00%
Oper. Margin -244.88%
Profit Margin 0.00%
Shs Outstand 82.26M
Shs Float 55.05M
Insider Own 2.08%
Instit Own 110.48%
Short Float 15.20%
Short Ratio 17.65
Short Interest 9.69M
52W High 103.00
vs 52W High -18.88%
52W Low 28.06
vs 52W Low 197.75%
Beta 2.06
Impl. Vol. 3.13%
Rel Volume 0.56
Avg Volume 646.61K
Volume 359.85K
Target (mean) $118.27
Tgt Median $118.50
Tgt Low $91.00
Tgt High $140.00
# Analysts 22
Recom Strong_buy
Prev Close $84.10
Price $83.55
Change -0.65%
About

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$118.27
Mean price target
2. Current target
$83.55
Latest analyst target
3. DCF / Fair value
$-30.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$83.55
Low
$91.00
High
$140.00
Mean
$118.27

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-06 init Canaccord Genuity — → Buy $106
2026-03-03 main UBS Buy → Buy $128
2026-03-02 main Citigroup Buy → Buy $120
2026-03-02 main Stephens & Co. Overweight → Overweight $100
2026-02-26 main BTIG Buy → Buy $134
2026-02-26 main Piper Sandler Overweight → Overweight $140
2026-02-03 reit BTIG Buy → Buy $138
2026-01-28 main Barclays Overweight → Overweight $133
2026-01-15 reit BTIG Buy → Buy $138
2026-01-06 down Wolfe Research Outperform → Peer Perform —
2025-12-22 main B. Riley Securities Buy → Buy $117
2025-12-16 main RBC Capital Outperform → Outperform $103
2025-12-11 main Stephens & Co. Overweight → Overweight $110
2025-12-11 main Mizuho Outperform → Outperform $120
2025-12-10 main JP Morgan Overweight → Overweight $125
2025-12-09 main Jefferies Buy → Buy $122
2025-12-09 main Citigroup Buy → Buy $110
2025-12-09 main Wells Fargo Overweight → Overweight $116
2025-12-09 main Truist Securities Buy → Buy $116
2025-12-09 main Oppenheimer Outperform → Outperform $120
News
RSS: Latest KYMR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-11 RIDLOFF ELENA Director — 3,000 $31.20 $93,600
2026-05-11 RIDLOFF ELENA Director — 3,000 $87.00 $261,000
2026-04-29 MAINOLFI NELLO Chief Executive Officer — 30,000 $2.08 $62,400
2026-04-29 MAINOLFI NELLO Chief Executive Officer — 30,000 $80.74 $2,435,377
2026-04-22 CHADWICK JEREMY G Chief Operating Officer — 300 $30.17 $11,717
2026-04-22 CHADWICK JEREMY G Chief Operating Officer — 300 $90.00 $27,000
2026-04-15 CHADWICK JEREMY G Chief Operating Officer — 6,551 $30.17 $225,437
2026-04-15 CHADWICK JEREMY G Chief Operating Officer — 6,551 $90.00 $589,598
2026-04-14 GOODMAN NOAH Officer — 1,347 $90.00 $121,230
2026-04-10 GOODMAN NOAH Officer — 10,264 $86.62 $897,782
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
39.21
-16.70%
47.07
-40.11%
78.59
+67.84%
46.83
Operating Revenue
39.21
-16.70%
47.07
-40.11%
78.59
+67.84%
46.83
Operating Expense
384.75
+26.65%
303.78
+24.44%
244.12
+17.32%
208.08
Research And Development
316.57
+31.77%
240.25
+27.06%
189.08
+15.12%
164.25
Selling General And Administration
68.19
+7.32%
63.53
+15.43%
55.04
+25.57%
43.83
General And Administrative Expense
68.19
+7.32%
63.53
+15.43%
55.04
+25.57%
43.83
Other Gand A
68.19
+7.32%
63.53
+15.43%
55.04
+25.57%
43.83
Total Expenses
384.75
+26.65%
303.78
+24.44%
244.12
+17.32%
208.08
Operating Income
-345.54
-34.60%
-256.71
-55.08%
-165.53
-2.65%
-161.26
Total Operating Income As Reported
-349.40
-33.54%
-261.63
-58.06%
-165.53
-2.65%
-161.26
EBITDA
-302.67
-39.97%
-216.24
-51.00%
-143.20
+5.57%
-151.66
Normalized EBITDA
-298.81
-41.41%
-211.31
-47.56%
-143.20
+5.57%
-151.66
Reconciled Depreciation
8.31
+12.75%
7.37
+106.82%
3.56
+19.75%
2.98
EBIT
-310.98
-39.07%
-223.61
-52.36%
-146.77
+5.09%
-154.63
Total Unusual Items
-3.85
+21.73%
-4.92
0.00
0.00
Total Unusual Items Excluding Goodwill
-3.85
+21.73%
-4.92
0.00
0.00
Special Income Charges
-3.85
+21.73%
-4.92
0.00
0.00
Impairment Of Capital Assets
3.85
-21.73%
4.92
0.00
0.00
Net Income
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Pretax Income
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Net Non Operating Interest Income Expense
38.05
+0.72%
37.78
+103.45%
18.57
+187.97%
6.45
Interest Expense Non Operating
0.37
+48.59%
0.25
+27.04%
0.20
+11.36%
0.18
Net Interest Income
38.05
+0.72%
37.78
+103.45%
18.57
+187.97%
6.45
Interest Expense
0.37
+48.59%
0.25
+27.04%
0.20
+11.36%
0.18
Interest Income Non Operating
38.42
+1.03%
38.03
+102.65%
18.76
+183.27%
6.62
Interest Income
38.42
+1.03%
38.03
+102.65%
18.76
+183.27%
6.62
Other Income Expense
-3.85
+21.73%
-4.92
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Net Income From Continuing Operation Net Minority Interest
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Net Income From Continuing And Discontinued Operation
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Net Income Continuous Operations
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Normalized Income
-307.50
-40.45%
-218.93
-48.97%
-146.96
+5.07%
-154.81
Net Income Common Stockholders
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Diluted EPS
-3.69
-23.83%
-2.98
-18.25%
-2.52
+12.20%
-2.87
Basic EPS
-3.69
-23.83%
-2.98
-18.25%
-2.52
+12.20%
-2.87
Basic Average Shares
84.49
+12.59%
75.04
+28.58%
58.37
+8.22%
53.93
Diluted Average Shares
84.49
+12.59%
75.04
+28.58%
58.37
+8.22%
53.93
Diluted NI Availto Com Stockholders
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,742.81
+78.20%
978.03
+69.87%
575.76
-4.54%
603.13
Current Assets
871.21
+70.74%
510.27
+25.89%
405.32
-3.36%
419.42
Cash Cash Equivalents And Short Term Investments
848.28
+73.56%
488.74
+30.37%
374.88
-7.93%
407.17
Cash And Cash Equivalents
357.01
+196.88%
120.26
+9.36%
109.97
+60.78%
68.39
Other Short Term Investments
491.26
+33.32%
368.49
+39.10%
264.92
-21.80%
338.77
Receivables
—
0.95
-94.95%
18.76
+639.53%
2.54
Accounts Receivable
—
0.00
-100.00%
15.00
0.00
Other Receivables
—
0.95
-74.83%
3.76
+48.29%
2.54
Prepaid Assets
—
—
—
—
Other Current Assets
22.94
+6.57%
21.52
+84.38%
11.67
+20.19%
9.71
Total Non Current Assets
871.60
+86.33%
467.77
+174.44%
170.44
-7.23%
183.72
Net PPE
85.53
-12.61%
97.86
-3.18%
101.08
+354.43%
22.24
Gross PPE
107.65
-5.52%
113.94
+2.17%
111.52
+282.75%
29.14
Accumulated Depreciation
-22.13
-37.67%
-16.07
-53.96%
-10.44
-51.46%
-6.89
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
47.41
-10.46%
52.95
+494.29%
8.91
Machinery Furniture Equipment
10.92
-8.93%
11.99
+43.28%
8.37
+21.39%
6.90
Construction In Progress
—
—
—
1.15
Other Properties
53.74
-7.24%
57.93
+36.63%
42.40
+666.88%
5.53
Leases
42.99
-2.32%
44.01
+464.09%
7.80
+0.00%
7.80
Investments And Advances
771.16
+112.93%
362.16
+489.51%
61.43
-59.67%
152.33
Other Non Current Assets
14.91
+92.59%
7.74
-2.33%
7.93
-13.32%
9.15
Total Liabilities Net Minority Interest
163.15
+14.56%
142.42
-21.22%
180.79
+60.01%
112.98
Current Liabilities
83.21
+22.79%
67.77
-20.92%
85.69
+20.11%
71.34
Payables And Accrued Expenses
46.29
+13.30%
40.86
-0.20%
40.94
+28.59%
31.84
Payables
4.01
-32.96%
5.99
-15.35%
7.08
+63.21%
4.33
Accounts Payable
4.01
-32.96%
5.99
-15.35%
7.08
+63.21%
4.33
Current Accrued Expenses
42.27
+21.24%
34.87
+2.96%
33.86
+23.13%
27.50
Current Debt And Capital Lease Obligation
13.76
+4.91%
13.11
+106.65%
6.34
+60.92%
3.94
Current Capital Lease Obligation
13.76
+4.91%
13.11
+106.65%
6.34
+60.92%
3.94
Current Deferred Liabilities
22.93
+68.86%
13.58
-64.16%
37.88
+7.44%
35.26
Current Deferred Revenue
22.93
+68.86%
13.58
-64.16%
37.88
+7.44%
35.26
Other Current Liabilities
0.24
+8.52%
0.22
-57.44%
0.52
+72.94%
0.30
Total Non Current Liabilities Net Minority Interest
79.94
+7.08%
74.65
-21.50%
95.10
+128.38%
41.64
Long Term Debt And Capital Lease Obligation
68.50
-8.24%
74.65
-4.70%
78.33
+484.89%
13.39
Long Term Capital Lease Obligation
68.50
-8.24%
74.65
-4.70%
78.33
+484.89%
13.39
Non Current Deferred Liabilities
11.44
0.00
-100.00%
16.77
-40.11%
28.00
Non Current Deferred Revenue
11.44
0.00
-100.00%
16.77
-40.11%
28.00
Other Non Current Liabilities
—
—
—
0.25
Stockholders Equity
1,579.66
+89.04%
835.62
+111.56%
394.97
-19.42%
490.15
Common Stock Equity
1,579.66
+89.04%
835.62
+111.56%
394.97
-19.42%
490.15
Capital Stock
0.01
+14.29%
0.01
+16.67%
0.01
+0.00%
0.01
Common Stock
0.01
+14.29%
0.01
+16.67%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
—
—
Share Issued
81.32
+25.32%
64.89
+16.74%
55.59
+0.99%
55.04
Ordinary Shares Number
81.32
+25.32%
64.89
+16.74%
55.59
+0.99%
55.04
Additional Paid In Capital
2,643.82
+66.10%
1,591.71
+71.84%
926.27
+5.39%
878.88
Retained Earnings
-1,065.96
-41.26%
-754.61
-42.18%
-530.75
-38.29%
-383.79
Gains Losses Not Affecting Retained Earnings
1.80
+221.21%
-1.49
-169.02%
-0.55
+88.85%
-4.95
Other Equity Adjustments
1.80
+221.21%
-1.49
-169.02%
-0.55
+88.85%
-4.95
Total Equity Gross Minority Interest
1,579.66
+89.04%
835.62
+111.56%
394.97
-19.42%
490.15
Total Capitalization
1,579.66
+89.04%
835.62
+111.56%
394.97
-19.42%
490.15
Working Capital
788.00
+78.08%
442.50
+38.44%
319.63
-8.17%
348.07
Invested Capital
1,579.66
+89.04%
835.62
+111.56%
394.97
-19.42%
490.15
Total Debt
82.25
-6.28%
87.76
+3.65%
84.67
+388.46%
17.34
Capital Lease Obligations
82.25
-6.28%
87.76
+3.65%
84.67
+388.46%
17.34
Net Tangible Assets
1,579.66
+89.04%
835.62
+111.56%
394.97
-19.42%
490.15
Tangible Book Value
1,579.66
+89.04%
835.62
+111.56%
394.97
-19.42%
490.15
Available For Sale Securities
771.16
+112.93%
362.16
+489.51%
61.43
-59.67%
152.33
Investmentin Financial Assets
771.16
+112.93%
362.16
+489.51%
61.43
-59.67%
152.33
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-232.89
-19.74%
-194.50
-89.16%
-102.83
+32.83%
-153.09
Cash Flow From Continuing Operating Activities
-232.89
-19.74%
-194.50
-89.16%
-102.83
+32.83%
-153.09
Net Income From Continuing Operations
-311.35
-39.08%
-223.86
-52.32%
-146.96
+5.07%
-154.81
Depreciation Amortization Depletion
8.31
+12.75%
7.37
+106.82%
3.56
+19.75%
2.98
Depreciation And Amortization
8.31
+12.75%
7.37
+106.82%
3.56
+19.75%
2.98
Stock Based Compensation
59.90
+8.89%
55.01
+27.58%
43.12
+21.53%
35.48
Asset Impairment Charge
3.86
-21.71%
4.92
0.00
0.00
Operating Gains Losses
—
—
-5.23
-688.19%
0.89
Gain Loss On Investment Securities
—
—
-5.23
-688.19%
0.89
Gain Loss On Sale Of PPE
—
—
0.00
0.00
Change In Working Capital
15.27
+163.69%
-23.97
-993.74%
2.68
+107.13%
-37.62
Change In Receivables
0.95
-94.68%
17.82
+209.79%
-16.23
-575.80%
-2.40
Changes In Account Receivables
0.00
-100.00%
15.00
+200.00%
-15.00
0.00
Change In Prepaid Assets
-2.36
+73.48%
-8.90
-354.00%
-1.96
-97.68%
-0.99
Change In Payables And Accrued Expense
5.41
+39.76%
3.87
-25.78%
5.22
+9.35%
4.77
Change In Accrued Expense
7.39
+76.72%
4.18
+31.45%
3.18
-29.63%
4.52
Change In Payable
-1.97
-543.00%
-0.31
-115.06%
2.04
+705.53%
0.25
Change In Account Payable
-1.97
-543.00%
-0.31
-115.06%
2.04
+705.53%
0.25
Change In Other Working Capital
13.64
+133.10%
-41.22
-433.35%
-7.73
+79.94%
-38.52
Change In Other Current Assets
2.67
+4.92%
2.54
-47.03%
4.80
+827.85%
0.52
Change In Other Current Liabilities
-5.04
-362.47%
1.92
-89.66%
18.58
+1950.80%
-1.00
Investing Cash Flow
-521.06
-28.95%
-404.08
-388.86%
139.89
+581.74%
20.52
Cash Flow From Continuing Investing Activities
-521.06
-28.95%
-404.08
-388.86%
139.89
+581.74%
20.52
Net PPE Purchase And Sale
-1.45
+88.71%
-12.84
+62.77%
-34.48
-1115.80%
-2.84
Purchase Of PPE
-1.45
+88.71%
-12.84
+62.77%
-34.48
-1115.80%
-2.84
Capital Expenditure
-1.45
+88.71%
-12.84
+62.77%
-34.48
-1115.80%
-2.84
Net Investment Purchase And Sale
-519.61
-32.81%
-391.24
-324.38%
174.37
+646.59%
23.36
Purchase Of Investment
-1,007.63
-11.81%
-901.23
-376.46%
-189.15
+57.59%
-445.97
Sale Of Investment
488.02
-4.31%
509.99
+40.29%
363.52
-22.55%
469.33
Financing Cash Flow
990.71
+62.72%
608.85
+14424.12%
4.19
-97.26%
153.00
Cash Flow From Continuing Financing Activities
990.71
+62.72%
608.85
+14424.12%
4.19
-97.26%
153.00
Net Issuance Payments Of Debt
-1.49
+5.20%
-1.58
-1973.68%
-0.08
+93.27%
-1.13
Repayment Of Debt
-1.49
+5.20%
-1.58
-1973.68%
-0.08
+93.27%
-1.13
Long Term Debt Payments
-1.49
+5.20%
-1.58
-1973.68%
-0.08
+93.27%
-1.13
Net Long Term Debt Issuance
-1.49
+5.20%
-1.58
-1973.68%
-0.08
+93.27%
-1.13
Net Common Stock Issuance
928.90
+55.69%
596.62
0.00
-100.00%
149.82
Proceeds From Stock Option Exercised
63.31
+358.47%
13.81
+223.52%
4.27
-0.84%
4.30
Net Other Financing Charges
—
—
—
—
Changes In Cash
236.76
+2204.69%
10.27
-75.10%
41.25
+101.89%
20.43
Beginning Cash Position
126.05
+8.87%
115.78
+55.35%
74.53
+37.77%
54.09
End Cash Position
362.81
+187.83%
126.05
+8.87%
115.78
+55.35%
74.53
Free Cash Flow
-234.34
-13.02%
-207.34
-51.01%
-137.31
+11.94%
-155.92
Interest Paid Supplemental Data
0.31
+51.46%
0.21
+27.16%
0.16
-9.50%
0.18
Amortization Of Securities
-8.88
+36.50%
-13.98
-167.41%
-5.23
-688.19%
0.89
Common Stock Issuance
928.90
+55.69%
596.62
0.00
-100.00%
149.82
Issuance Of Capital Stock
928.90
+55.69%
596.62
0.00
-100.00%
149.82
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category